



## Innate Immunosurveillance of Cancer

Guest Editor:

**Dr. Venkateshwar G.  
Keshamouni**

Department of Internal Medicine,  
Pulmonary & Critical Care  
Division, Medical School,  
University of Michigan, Ann  
Arbor, MI 48109, USA

Deadline for manuscript  
submissions:

**closed (31 December 2021)**

### Message from the Guest Editor

Innate immune cells are the first line of defense against cancer development and infections. These cells respond to initial perturbations in the tissue, which can result in either control or even prevention of tumor initiation and progression. But, as tumors develop immune evasive mechanisms, innate immune cells can also facilitate tumor progression and metastasis. Therefore, understanding the influence and mechanisms underlying both pro- and anti-tumor effects of the innate immune system is crucial in fighting cancer.

This Special Issue will collect a series of reviews and original articles describing basic science, preclinical, and clinical investigations, covering all aspects of innate immune surveillance from tumor initiation, progression, and metastasis. Potential topics include but are not limited to tumor immune microenvironments with emphasis on innate immune cells, innate immune receptors and signaling, molecular mechanisms of innate immune evasion, engineering innate immune cells, novel immunotherapies, and mechanisms of resistance to immunotherapies.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Samuel C. Mok

Department of Gynecologic  
Oncology and Reproductive  
Medicine, The University of Texas  
MD Anderson Cancer Center,  
Houston, TX 77030, USA

## Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

**Journal Rank:** JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

## Contact Us

---

Cancers Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/cancers](http://mdpi.com/journal/cancers)  
[cancers@mdpi.com](mailto:cancers@mdpi.com)  
[X@Cancers\\_MDPI](https://twitter.com/Cancers_MDPI)